Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.6%

12 terminated/withdrawn out of 88 trials

Success Rate

78.2%

-8.3% vs industry average

Late-Stage Pipeline

23%

20 trials in Phase 3/4

Results Transparency

72%

31 of 43 completed trials have results

Key Signals

11 recruiting31 with results10 terminated

Enrollment Performance

Analytics

Phase 2

37(48.1%)

Phase 3

16(20.8%)

Phase 1

15(19.5%)

N/A

5(6.5%)

Phase 4

4(5.2%)

77Total

Phase 2(37)

Phase 3(16)

Phase 1(15)

N/A(5)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (88)

Showing 20 of 88 trials

NCT03556332Phase 2Active Not Recruiting

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Role: collaborator

NCT06083922Phase 2Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Role: collaborator

NCT04667663Phase 1Active Not Recruiting

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Role: collaborator

NCT02772588Phase 2Completed

AASUR in High Risk Prostate Cancer

Role: collaborator

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT03236428Phase 2Active Not Recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Role: collaborator

NCT04268498Phase 2Active Not Recruiting

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

Role: collaborator

NCT07488156Not ApplicableNot Yet Recruiting

Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder

Role: collaborator

NCT02938520Phase 3Active Not Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Role: collaborator

NCT06066346Phase 2Recruiting

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

Role: collaborator

NCT06549634Completed

Biomarkers of AKI in Patients Receiving Daratumumab

Role: collaborator

NCT03283917Phase 1Active Not Recruiting

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Role: collaborator

NCT05117931Phase 2Active Not Recruiting

A Study of Amivantamab in People With Esophagogastric Cancer

Role: collaborator

NCT03503344Phase 2Completed

Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

Role: collaborator

NCT05601973Phase 2Active Not Recruiting

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Role: collaborator

NCT04983030Phase 1Active Not Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Role: collaborator

NCT02951052Phase 3Active Not Recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Role: collaborator

NCT03696160Phase 3Completed

The Late Presenter Treatment Optimisation Study

Role: collaborator

NCT03290950Phase 2Active Not Recruiting

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT07110844Phase 2Recruiting

Teclistamab-Daratumumab in AL Amyloidosis

Role: collaborator